Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

(2017) M. Sznol et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

(2017) R. C. Newton et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

(2010) K. Tamura et al.   ANNALS OF ONCOLOGY

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells

(2010) K. Juelke et al.   BLOOD

Human    T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement

(2010) A. Maniar et al.   BLOOD

CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells

(2010) H. Narazaki et al.   BLOOD

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

(2010) Juan Dubrot et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines

(2010) R. K. Sharma et al.   CANCER RESEARCH

Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo

(2010) Weijuan Gong et al.   Cellular & Molecular Immunology

E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells

(2010) Chisako Yamauchi et al.   INTERNATIONAL JOURNAL OF CANCER

Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy

(2010) Filippo Bellati et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

(2010) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

(2010) K. Takeda et al.   JOURNAL OF IMMUNOLOGY

Regulation of Granulocyte and Macrophage Populations of Murine Bone Marrow Cells by G-CSF and CD137 Protein

(2010) Dongsheng Jiang et al.   PLoS One

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

(2009) R. Houot et al.   BLOOD

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells

(2009) T. Baessler et al.   BLOOD

Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

(2009) Philippe Bedard et al.   CURRENT CANCER DRUG TARGETS

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

(2009) Oihana Murillo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2009) Neil L. Spector et al.   JOURNAL OF CLINICAL ONCOLOGY

CD137 Promotes Proliferation and Survival of Human B Cells

(2009) X. Zhang et al.   JOURNAL OF IMMUNOLOGY

Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer

(2009) Nicolas Acquavella et al.   JOURNAL OF IMMUNOTHERAPY

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies

(2009) T. S. Bekaii-Saab et al.   MOLECULAR CANCER THERAPEUTICS

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD

Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies

(2008) W. Lin et al.   BLOOD

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

(2008) Aruna Mani et al.   BREAST CANCER RESEARCH AND TREATMENT

Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates

(2008) Nikesh Kotecha et al.   CANCER CELL

Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells

(2008) A. Belkhiri et al.   CLINICAL CANCER RESEARCH

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma

(2008) O. Murillo et al.   CLINICAL CANCER RESEARCH

Current perspective – Trastuzumab

(2008) Peter S. Hall et al.   EUROPEAN JOURNAL OF CANCER

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY